Ted Cruz's regulatory outsourcing plan for the FDA stirs controversy

Ted Cruz's plan to essentially outsource the drug approval process to other countries through a new reciprocal approval approach has been stirring a lot of discussion online. Vox starts with a largely upbeat tone on the prospect of faster approvals for new drugs, then turns to some key criticisms. "This would completely marginalize the FDA," said Aaron Kesselheim, a professor of medicine at Harvard Medical School. "It would allow the decision-making in other countries to have full power over the market in the United States." It would also largely eliminate the FDA's final word on approvals, giving Congress the right to override any of its decisions by a majority vote. Story

Suggested Articles

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.

The top-line readout appears to justify the risk the partners took when they advanced the drug despite missing the primary endpoint in phase 2.